Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alzamend Neuro, Inc

0.9349
-0.0050-0.53%
Volume:155.61K
Turnover:149.06K
Market Cap:6.17M
PE:-0.23
High:1.01
Open:0.9700
Low:0.9006
Close:0.9399
Loading ...

Company Profile

Company Name:
Alzamend Neuro, Inc
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
6
Office Location:
3480 Peachtree Road NE,Second Floor, Suite 103,Atlanta,Georgia,United States
Zip Code:
30326
Fax:
- -
Introduction:
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Directors

Name
Position
Stephan Jackman
Chief Executive Officer and Director
William B. Horne
Chairman of the Board
Henry C. W. Nisser
Executive Vice President, General Counsel and Director
Andrew H. Woo
Director
Jeffrey Oram
Director
Lynne Fahey McGrath
Director
Mark Gustafson
Director

Shareholders

Name
Position
Stephan Jackman
Chief Executive Officer and Director
David Katzoff
Chief Financial Officer
Kenneth S. Cragun
Senior Vice President of Finance
Henry C. W. Nisser
Executive Vice President, General Counsel and Director